DIAGNOS and Labtician Bolster Diabetic Eye Care
Company Announcements

DIAGNOS and Labtician Bolster Diabetic Eye Care

Diagnos (TSE:ADK) has released an update.

DIAGNOS Inc. has renewed its distribution agreement with Labtician, celebrating the integration of its AI-based image analysis for diabetic retinopathy into Labtician’s offerings in Ontario. This collaboration aims to enhance eye care for diabetics by improving access to screenings through Ontario’s health system, thus addressing patient compliance and reducing vision loss risks. The partnership reaffirms both companies’ commitment to advancing healthcare solutions and expanding DIAGNOS’ presence in the Canadian market.

For further insights into TSE:ADK stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskDiagnos Inc. Grants Stock Options to Leadership
TipRanks Canadian Auto-Generated NewsdeskDIAGNOS Inc. Shareholders Approve Key Proposals
TipRanks Canadian Auto-Generated NewsdeskDiagnos Insider Ownership Shifts Post-Share Placement
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App